Načítá se...
Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation
Cancer treatments often require combinations of molecularly targeted agents to be effective. mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors have been shown to be effective in limiting tumor growth, and here we define part of the cooperative action of this drug combination. More than 60 h...
Uloženo v:
| Vydáno v: | Mol Cancer Ther |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5587368/ https://ncbi.nlm.nih.gov/pubmed/28522584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0171 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|